Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
01 Agosto 2024 - 6:05AM
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical
company revolutionizing the delivery of therapies to the back of
the eye through the suprachoroidal space (SCS®), announced today
that its second quarter 2024 financial results will be reported on
Monday, August 12, 2024, after the close of the financial markets.
In lieu of a second quarter 2024 conference
call, the Company hosted a Suprachoroidal Delivery Key Opinion
Leader Webinar on Wednesday, July 24, 2024. The replay of this
event is available on the Clearside website under the Investors
section: Events and Presentations. Quarterly earnings conference
calls are expected to resume with the third quarter 2024 financial
results.
About Clearside Biomedical,
Inc.
Clearside Biomedical, Inc. is a
biopharmaceutical company revolutionizing the delivery of therapies
to the back of the eye through the suprachoroidal space (SCS®).
Clearside’s SCS injection platform, utilizing the Company’s
patented SCS Microinjector®, enables an in-office, repeatable,
non-surgical procedure for the targeted and compartmentalized
delivery of a wide variety of therapies to the macula, retina, or
choroid to potentially preserve and improve vision in patients with
sight-threatening eye diseases. Clearside is developing its own
pipeline of small molecule product candidates for administration
via its SCS Microinjector. The Company’s lead program, CLS-AX
(axitinib injectable suspension), for the treatment of neovascular
age-related macular degeneration (wet AMD), is in Phase 2b clinical
testing. Clearside developed and gained approval for its first
product, XIPERE® (triamcinolone acetonide injectable suspension)
for suprachoroidal use, which is available in the U.S. through a
commercial partner. Clearside also strategically partners its SCS
injection platform with companies utilizing other ophthalmic
therapeutic innovations. For more information, please visit
clearsidebio.com and follow us on LinkedIn and X.
Investor and Media Contacts:Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024